The National Cancer Institute (NCI) awarded a Project Grant totaling $336,000.00 to the Van Andel Research Institute (VAI) to conduct research on the role of germline genetic variation and viral exposures as determinants of hematological disease predisposition, particularly for acute myeloid leukemia (AML) in pediatric patients. The project, titled "DISSECTING THE ROLE OF GERMLINE GENETIC VARIATION AND VIRAL EXPOSURES AS DETERMINANTS OF HEMATOLOGICAL DISEASE PREDISPOSITION," will run from July 1, 2024 to June 30, 2026.
The research aims to characterize germline regulatory, splicing, and structural variants as potential catalysts of risk for leukemia and related preleukemic conditions. This effort will leverage large datasets from the Gabriella Miller Kids First (GMKF) consortium and the Include cohorts, as well as data from the Project: Every Child pediatric clinical trials, to enable the necessary sample sizes and computational infrastructure to investigate these factors. The findings could inform strategies for screening or prophylaxis to mitigate predisposition risk.
Generated 2/25/25, 4:36 AM